The study demonstrated in excess of 90% VISTA receptor occupancy over the entire Q2W dosing interval where PK simulations would predict similar receptor occupancy even at 750mg Q2W dosing ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed signs of anti-tumor activity, including an unconfirmed partial ...

As of the April 7, 2025 data cut-off, results showed: BDC-3042 was well tolerated up to the highest dose level tested (10 mg/kg q2w), with no dose-limiting toxicities observed. Across all dose cohorts ...